Deutsche Bank’s MoonLake Immunotherapeutics MLTX Stock Holding History

Deutsche Bank’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.2K	Hold	2,052	–	–	﹤0.01%	3500
2025 Q4	$27K	Sell	2,052 -288	-12%	-$3.4K	﹤0.01%	3504
2025 Q3	$16.8K	Buy	2,340 +785	+50%	+$40.9K	﹤0.01%	3509
2025 Q2	$73.4K	Buy	1,555 +652	+72%	+$26.6K	﹤0.01%	3359
2025 Q1	$35.3K	Hold	903	–	–	﹤0.01%	3430
2024 Q4	$48.9K	Buy	903 +338	+60%	+$17.3K	﹤0.01%	3415
2024 Q3	$28.5K	Hold	565	–	–	﹤0.01%	3441
2024 Q2	$24.8K	Hold	565	–	–	﹤0.01%	3409
2024 Q1	$28.4K	Hold	565	–	–	﹤0.01%	3477
2023 Q4	$34.1K	Buy	+565	New	+$29.1K	﹤0.01%	3455

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank's MLTX Position: Q1 2026 in Review

Deutsche Bank held its MoonLake Immunotherapeutics (MLTX) position steady in Q1 2026 at 2,052 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3500.

Deutsche Bank first reported a position in MLTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $73.4K in Q2 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Deutsche Bank held 2,052 shares of MoonLake Immunotherapeutics worth $38.2K as of Q1 2026.
Deutsche Bank left its MoonLake Immunotherapeutics share count unchanged in Q1 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3500 holding.
Deutsche Bank first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 10 quarters since.
Deutsche Bank's MoonLake Immunotherapeutics position peaked at $73.4K in Q2 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.